was committed to the development of academic and medical sciences not only in Japan but also throughout the world. His first-in-human study of a statin was the starting point, and statins have been shown to be effective in preventing atherosclerotic cardiovascular disease and have played a major role in public health worldwide. In addition, patients with FH, who have atherosclerotic cardiovascular disease at a young age, received tremendous benefit from statins by improving their prognosis dramatically. Dr Yamamoto's development of LDL apheresis enabled selective removal of LDL for the treatment of homozygous FH. The therapeutic indication of LDL apheresis is expanding to include such conditions as severe heterozygous FH, arteriosclerosis obliterans, and focal glomerulosclerosis. The number of patients receiving benefits from these techniques has been also increasing dramatically.
Having learnt a lot under Dr Akira Yamamoto, I will proudly continue to work on FH medical care. Dr Akira Yamamoto, thank you very much.
